Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats
| Autor: | Serge Adnot, Bernadette Raffestin, Saadia Eddahibi, Anne-Charlotte Le Monnier de Gouville |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Pharmacology
medicine.medical_specialty business.industry Vasodilation Hypoxia (medical) medicine.disease Pulmonary hypertension Nitric oxide chemistry.chemical_compound Endocrinology chemistry Atrial natriuretic peptide Right ventricular hypertrophy Internal medicine cGMP-specific phosphodiesterase type 5 medicine Sodium nitroprusside medicine.symptom business medicine.drug |
| Zdroj: | British Journal of Pharmacology. 125:681-688 |
| ISSN: | 0007-1188 |
| DOI: | 10.1038/sj.bjp.0702124 |
| Popis: | 1. Cyclic guanosine 3'-5'-monophosphate (cyclic GMP) is the second messenger of important physiologically active mediators controlling the pulmonary vascular tone. To potentiate the effects of cyclic GMP on the pulmonary vasculature, we used DMPPO, a new selective PDE-5 inhibitor, and examined its action in a rat model of hypoxic pulmonary hypertension. 2. Levels of cyclic GMP measured during baseline conditions at 5 and 60 min of perfusion were similar in the perfusate of isolated lungs from normoxic and chronically hypoxic rats and did not differ with time. Pretreatment with DMPPO (1 microM) induced a larger increase in cyclic GMP concentration in the perfusate from chronically hypoxic rat lungs (31+/-36 at 5 min to 1821+/-83 pmol ml(-1) at 60 min) than in normoxic rat lungs (329+/-20 to 1281+/-127 pmol ml(-1), P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text